Source: Eur Respir Rev 2008; 17: 13-18
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Humbert M.. Dual endothelin receptor antagonism: setting standards in PAH. Eur Respir Rev 2008; 17: 13-18

Member's Comments

No comment yet.

Related content which might interest you: Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Looking to the future: a new decade of pulmonary arterial hypertension therapy Source: Eur Respir Rev 2011; 20: 262-269 Year: 2011 Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005 Dual endothelin receptor blockade: advances in pulmonary disease Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience Year: 2008 Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005 Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005